This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Arthur DW , Winter KA , Kuerer HM , Haffty BG , Cuttino LW , Todor DA , Simone NL , Hayes SB , Woodward WA , McCormick B , Cohen RJ , Sahijdak WM , Canaday DJ , Brown DR , Currey AD , Fisher CM , Jagsi R , White J
NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence
Int J Radiat Oncol Biol Phys. 2017 Aug 01;98(5) :1028-1035
PMID: 28721885 PMCID: PMC5572128 URL: https://www.ncbi.nlm.nih.gov/pubmed/28721885
AbstractPURPOSE: To determine the associated toxicity, tolerance, and safety of partial-breast reirradiation. METHODS AND MATERIALS: Eligibility criteria included in-breast recurrence occurring >1 year after whole-breast irradiation, <3 cm, unifocal, and resected with negative margins. Partial-breast reirradiation was targeted to the surgical cavity plus 1.5 cm; a prescription dose of 45 Gy in 1.5 Gy twice daily for 30 treatments was used. The primary objective was to evaluate the rate of grade >/=3 treatment-related skin, fibrosis, and/or breast pain adverse events (AEs), occurring </=1 year from re-treatment completion. A rate of >/=13% for these AEs in a cohort of 55 patients was determined to be unacceptable (86% power, 1-sided alpha = 0.07). RESULTS: Between 2010 and 2013, 65 patients were accrued, and the first 55 eligible and with 1 year follow-up were analyzed. Median age was 68 years. Twenty-two patients had ductal carcinoma in situ, and 33 had invasive disease: 19 </=1 cm, 13 >1 to </=2 cm, and 1 >2 cm. All patients were clinically node negative. Systemic therapy was delivered in 51%. All treatment plans underwent quality review for contouring accuracy and dosimetric compliance. All treatment plans scored acceptable for tumor volume contouring and tumor volume dose-volume analysis. Only 4 (7%) scored unacceptable for organs at risk contouring and organs at risk dose-volume analysis. Treatment-related skin, fibrosis, and/or breast pain AEs were recorded as grade 1 in 64% and grade 2 in 7%, with only 1 (<2%) grade >/=3 and identified as grade 3 fibrosis of deep connective tissue. CONCLUSION: Partial-breast reirradiation with 3-dimensional conformal radiation therapy after second lumpectomy for patients experiencing in-breast failures after whole-breast irradiation is safe and feasible, with acceptable treatment quality achieved. Skin, fibrosis, and breast pain toxicity was acceptable, and grade 3 toxicity was rare.
Notes1879-355x Arthur, Douglas W Winter, Kathryn A Kuerer, Henry M Haffty, Bruce G Cuttino, Laurie W Todor, Dorin A Simone, Nicole L Hayes, Shelly B Woodward, Wendy A McCormick, Beryl Cohen, Randi J Sahijdak, Walter M Canaday, Daniel J Brown, Doris R Currey, Adam D Fisher, Christine M Jagsi, Reshma White, Julia Journal Article United States Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1028-1035. doi: 10.1016/j.ijrobp.2017.03.016. Epub 2017 Mar 18.